Peptron Inc
KOSDAQ:087010
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
P
|
Peptron Inc
KOSDAQ:087010
|
6.8T KRW |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
214.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.8B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81.6T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.3B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
273.1B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.4B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.9B USD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
Peptron Inc
Glance View
Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care. At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Peptron Inc is 57.8%, which is above its 3-year median of 38.4%.
Over the last 3 years, Peptron Inc’s Gross Margin has increased from 57% to 57.8%. During this period, it reached a low of 30.2% on Sep 30, 2024 and a high of 57.8% on Oct 30, 2025.